Phase II Study of Weekly Oxaliplatin and High-dose Infusional 5-Fluorouracil plus Leucovorin in Pretreated Patients with Metastatic Colorectal Cancer

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 355-360

  Chiara, Silvana ^a   Nobile, M T ^a   Gozza, A ^a   Taveggia, P ^a   Heouaine, A ^a   Pastrone, I ^a   Percivale, P L ^a   Lionetto, R ^a   Sanguineti, O ^b   Rosso, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Sestri Levante   (Italy)

Author keywords

5 fluorouracil; Colorectal cancer; Dose intensity; Oxaliplatin; Phase II

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; INCIDENCE; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 10744224324     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Schmoll HJ, Büchele T, Grothey A and Dempke W: Where do we stand with 5-fluorouracil? Semin Oncol 26: 589-605, 1999.
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
3. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308, 1998.
4. Meta-Analysis Group in Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537-3541, 1998.
5. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JC: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-432, 1989.
6. Nobile MT, Barzacchi MC, Sanguineti O, Chiara S, Gozza A, Vincenti M, Lavarello A, Cognein P, Lionetto R, Percivale PL, Bertoglio S, Murolo C, Esposito M, Vannozzi MO and Rosso R: Activity of high-dose 24 h 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer. Anticancer Res 18: 517-522, 1998.
7. Fischel JL, Formento P, Ciccolini J, Rostagno P, Etienne MC, Catalin J and Milano G: Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Brit J Cancer 86: 1162-1168, 2002.
8. Culy CR, Clemett D and Wiseman LR. Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60: 895-924, 2000.
9. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL and Levi F: Phase III multicenter randomized trial of oxaliplatin added to chromomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000.
10. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
11. Janinis J, Papakostas P, Samelis G, Skarlos D, Papagioanopoulos P and Fountzilas G: Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 11: 163-167, 2000.
12. Rosati G, Rossi A, Tucci A, Pizza C and Manzione L: Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. Ann Oncol 12: 669-674, 2001.
13. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M and Gamelin E: Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6: 1205-1218, 2000.
14. Boisdron-Celle M, Craipeau MC, Brienza S, Delva R, Guerin-Meyer V, Cvitkovic E and Gamelin E: Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemother Pharmacol 49: 235-243, 2002.
15. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979.
16. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
17. Extra JM, Marty M, Brienza S and Misset JL: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25 (Suppl. 5): 13-22, 1998.
18. de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, Raymond E, Moreau S, Le Bail N and Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
19. Andrè T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-Andre G and de Gramont A: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimens. J Clin Oncol 17: 3560-3568, 1999.
20. Maindrault-Goebel F, Louvet C, Andrè T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M and de Gramont A: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 6). Eur J Cancer 35: 1338-1342, 1999.
21. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V and Krulik M: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in preated metastatic colorectal cancer. Annal Oncol 11: 1477-1483, 2000.
22. Grothey A, Deschler B, Kroening H et al: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Majo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (FUFOX) in advanced colorectal cancer. Proc Am Soc Clin Onc 2002; abstract no. 512 (available online at www.asco.org).